Whole‐exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene

As subsets of pheochromocytomas (PCCs) lack a defined molecular etiology, we sought to characterize the mutational landscape of PCCs to identify novel gene candidates involved in disease development. A discovery cohort of 15 PCCs wild type for mutations in PCC susceptibility genes underwent whole‐exome sequencing, and an additional 83 PCCs served as a verification cohort for targeted sequencing of candidate mutations. A low rate of nonsilent single nucleotide variants (SNVs) was detected (6.1/sample). Somatic HRAS and EPAS1 mutations were observed in one case each, whereas the remaining 13 cases did not exhibit variants in established PCC genes. SNVs aggregated in apoptosis‐related pathways, and mutations in COSMIC genes not previously reported in PCCs included ZAN, MITF, WDTC1, and CAMTA1. Two somatic mutations and one constitutional variant in the well‐established cancer gene lysine (K)‐specific methyltransferase 2D (KMT2D, MLL2) were discovered in one sample each, prompting KMT2D screening using focused exome‐sequencing in the verification cohort. An additional 11 PCCs displayed KMT2D variants, of which two were recurrent. In total, missense KMT2D variants were found in 14 (11 somatic, two constitutional, one undetermined) of 99 PCCs (14%). Five cases displayed somatic mutations in the functional FYR/SET domains of KMT2D, constituting 36% of all KMT2D‐mutated PCCs. KMT2D expression was upregulated in PCCs compared to normal adrenals, and KMT2D overexpression positively affected cell migration in a PCC cell line. We conclude that KMT2D represents a recurrently mutated gene with potential implication for PCC development. © 2015 The Authors. Genes, Chromosomes & Cancer Published by Wiley Periodicals, Inc.

[1]  P. Söderkvist,et al.  Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. , 2011, Endocrine-related cancer.

[2]  E. Lack.  Tumors of the adrenal glands and extraadrenal paraganglia , 2007 .

[3]  Jenny Welander,et al.  Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. , 2014, The Journal of clinical endocrinology and metabolism.

[4]  J. Benítez,et al.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.

[5]  H. Smeets,et al.  MLL2 mutation spectrum in 45 patients with Kabuki syndrome , 2011, Human mutation.

[6]  E. Letouzé,et al.  Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. , 2012, Human molecular genetics.

[7]  R. McLendon,et al.  KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation , 2013, Oncotarget.

[8]  A. Gimenez-Roqueplo,et al.  Paraganglioma and phaeochromocytoma: from genetics to personalized medicine , 2015, Nature Reviews Endocrinology.

[9]  D. Wieczorek,et al.  A mutation screen in patients with Kabuki syndrome , 2011, Human Genetics.

[10]  A. Valencia,et al.  Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy , 2013, Nature Genetics.

[11]  C. Croce,et al.  Knockdown of ALR (MLL2) Reveals ALR Target Genes and Leads to Alterations in Cell Adhesion and Growth , 2006, Molecular and Cellular Biology.

[12]  G. Pita,et al.  Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. , 2013, Human molecular genetics.

[13]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[14]  Patricia L. M. Dahia,et al.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma , 2010, Nature Genetics.

[15]  Natarajan Ganesan,et al.  Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon , 2010, Cancer Cell International.

[16]  Leyla Isik,et al.  Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. , 2009, Cancer research.

[17]  C. Larsson,et al.  Loss of Heterozygosity on the Short Arm of Chromosome 1 in Pheochromocytoma and Abdominal Paraganglioma , 2002, World Journal of Surgery.

[18]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[19]  W. Pavan,et al.  Frequent mutations in the MITF pathway in melanoma , 2009, Pigment cell & melanoma research.

[20]  Sampsa Hautaniemi,et al.  Candidate driver genes in microsatellite‐unstable colorectal cancer , 2012, International journal of cancer.

[21]  P. Rustin,et al.  Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. , 2014, Human molecular genetics.

[22]  P. Hellman,et al.  Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. , 2013, The Journal of clinical endocrinology and metabolism.

[23]  Li Shang,et al.  Genomic and molecular characterization of esophageal squamous cell carcinoma , 2014, Nature Genetics.

[24]  F. Galateau-Sallé,et al.  PHD2 mutation and congenital erythrocytosis with paraganglioma. , 2008, The New England journal of medicine.

[25]  Emily H Turner,et al.  Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome , 2010, Nature Genetics.

[26]  C. Larsson,et al.  Frequent EPAS1 / HIF2 a exons 9 and 12 mutations in non-familial pheochromocytoma , 2014 .

[27]  Min Gyu Lee,et al.  UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. , 2014, Cancer research.

[28]  Steven J. M. Jones,et al.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.

[29]  Qiang Feng,et al.  Identification of genomic alterations in oesophageal squamous cell cancer , 2014, Nature.

[30]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[31]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[32]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[33]  Rene H Medema,et al.  P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development , 2009, International journal of cancer.

[34]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[35]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[36]  P. Munson,et al.  Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. , 2004, Endocrine-related cancer.

[37]  V. Montori,et al.  Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review , 2015, Clinical endocrinology.

[38]  P. Dahia.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity , 2014, Nature Reviews Cancer.

[39]  P. Stephens,et al.  Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer , 2014, Journal of Clinical Pathology.

[40]  C. Larsson,et al.  Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. , 2012, Human molecular genetics.

[41]  M. Meyerson,et al.  The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.

[42]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.